knowledge -WSS

knowledge

author：Wikipedia 2025-10-01 04:13:06 - browse：92328

Adam's take main illustration — Molly Ferguson/STAT

This week, an encouraging turnaround for Ocular Therapeutix, a chat with Alnylam’s CEO defending changes to the HELIOS-B study and talking up its hypertension treatment, and quick takes on Amylyx and obesity stocks.

A Worst CEO gets some much-needed help

For most of last year, Ocular Therapeutix CEO Antony Mattessich promised shareholders that he was close to nailing down a lucrative pharma partnership that would pay for late-stage clinical trials of the company’s treatments for degenerative eye diseases. The deal never happened. I heard from many Ocular investors who were frustrated and angry about Mattesich’s poor job performance. He ended up earning a spot last year on my worst biopharma CEO list. It was an easy pick.

On Thursday, Ocular announced a meaningful “leadership update.” Mattessich is still the CEO, but let’s just say the company’s board decided to surround him with new executives and retinal experts with proven track records of getting stuff done.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： HCA sued by state AG for quality issues at Mission Health

WSS

Can sheer will power keep patients alive in their dying hours?

Stop Congress from blocking public access to science

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Experts study whether long Covid risk adds up with each reinfection

HCA sued by state AG for quality issues at Mission Health

Can sheer will power keep patients alive in their dying hours?

entertainment

knowledge

A Worst CEO gets some much-needed help

explore

Jerome Adams on the need for new antivirals for Covid

In Spain, a hospital brews its own CAR

Medicare details structure of new drug price negotiation program

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

BioMarin wins approval for gene therapy to treat hemophilia A

Three trends to watch in biotech in 2024

At least 13 dead in Texas as scorching temps continue

SNAP should offer more nutrition education

Dobbs anniversary: the lost opportunity of abortion as health care

How to keep neuroscience’s past racism from being its future

hotspot

SEC charges former device maker CEO with $41 million fraud

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Editas, Vertex strike deal on CRISPR

Medicare Advantage beneficiaries sue Humana over algorithm use

IVG is promising — but it won’t replace IVF quite yet

New oral drug delivery patch is modeled after octopus tentacles

hotspot

focus

leisure time

leisure time